Mendus
ISIN: SE0005003654 | Ticker: IMMU | LEI: 529900AFBGFR7ZB50J95
Country: Sweden
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
Served areaEurope
HeadquartersVästra Trädgårdsgatan 15, 11153 Stockholm – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 728,661,000.00 | 720,984,000.00 | 620,386,000.00 |
| Noncurrent Assets | N/A | 536,028,000.00 | 535,754,000.00 | 573,174,000.00 |
| Property Plant And Equipment | N/A | 1,705,000.00 | 2,109,000.00 | 13,899,000.00 |
| Goodwill | N/A | 108,350,000.00 | 108,350,000.00 | 108,350,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 424,091,000.00 | 424,091,000.00 | 424,091,000.00 |
| Other Noncurrent Receivables | N/A | 677,000.00 | 843,000.00 | 618,000.00 |
| Current Assets | N/A | 192,634,000.00 | 185,229,000.00 | 47,212,000.00 |
| Current Prepayments And Current Accrued Income Other Than Current Contract Assets | N/A | 4,760,000.00 | 10,214,000.00 | 1,919,000.00 |
| Other Current Receivables | N/A | 20,230,000.00 | 19,702,000.00 | 3,442,000.00 |
| Cash and cash equivalents | 14,032,000.00 | 167,643,000.00 | 155,313,000.00 | 41,851,000.00 |
| Equity And Liabilities | N/A | 728,661,000.00 | 720,984,000.00 | 620,386,000.00 |
| Equity | N/A | 661,094,000.00 | 656,742,000.00 | 514,439,000.00 |
| Issued Capital | N/A | 8,308,000.00 | 9,970,000.00 | 9,970,000.00 |
| Retained Earnings | N/A | -353,790,000.00 | -487,199,000.00 | -625,985,000.00 |
| Other Reserves | N/A | 3,532,000.00 | 3,637,000.00 | -182,000.00 |
| Additional Paidin Capital | N/A | 1,003,044,000.00 | 1,130,334,000.00 | 1,130,636,000.00 |
| Liabilities | N/A | 67,567,000.00 | 64,242,000.00 | 105,947,000.00 |
| Noncurrent Liabilities | N/A | 19,285,000.00 | 36,666,000.00 | 46,550,000.00 |
| Longterm Borrowings | N/A | 18,982,000.00 | 36,666,000.00 | 22,844,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 10,365,000.00 | 11,610,000.00 | 7,411,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | 13,857,000.00 | 10,510,000.00 | 15,610,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | N/A | 31,000.00 | 3,375,000.00 |
| Revenue From Rendering Of Services | N/A | 0.00 | 0.00 |
| Other Income | 0.00 | 31,000.00 | 3,375,000.00 |
| Profit Loss From Operating Activities | -86,027,000.00 | -130,100,000.00 | -133,684,000.00 |
| Finance Income | 0.00 | 0.00 | 163,000.00 |
| Finance Costs | 3,220,000.00 | 3,310,000.00 | 5,264,000.00 |
| Profit Loss Before Tax | -89,248,000.00 | -133,410,000.00 | -138,785,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -89,248,000.00 | -133,410,000.00 | -138,785,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -89,248,000.00 | -133,410,000.00 | -138,785,000.00 |
| Other Adjustments To Reconcile Profit Loss | N/A | 1,774,000.00 | 2,298,000.00 | -1,542,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -56,626,000.00 | -138,033,000.00 | -109,331,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 157,762,000.00 | 0.00 | N/A |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 464,000.00 | 1,361,000.00 | 12,097,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 157,298,000.00 | -1,361,000.00 | -12,324,000.00 |
| Proceeds From Issuing Shares | N/A | 0.00 | 141,242,000.00 | 0.00 |
| Cash Flows From Used In Financing Activities | N/A | 50,904,000.00 | 127,029,000.00 | 8,194,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 151,576,000.00 | -12,365,000.00 | -113,461,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 2,035,000.00 | 35,000.00 | 2,000.00 |
| Cash and cash equivalents | 14,032,000.00 | 167,643,000.00 | 155,313,000.00 | 41,851,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 02.04.24 | Erik Manting | Other | Other | SEK 425,111.04 |
| 02.04.24 | Dharminder Chahal | Other | Other | SEK 423,383.04 |
| 02.04.24 | Leopold Bertea | Other | Other | SEK 128,571.84 |
| 25.10.22 | Sven Arne Andreasson | Other | Sell | SEK 31,950.00 |
| 12.10.22 | Sven Arne Andreasson | Other | Sell | SEK 18,800.00 |
| 20.05.22 | Erik Manting | Other | Buy | SEK 86,347.47 |
| 19.05.22 | Ann-Charlotte Ferm | Other | Buy | SEK 215,900.00 |
| 19.05.22 | Erik Manting | Other | Buy | SEK 135,323.15 |
| 24.02.22 | Jeroen Rovers | Other | Buy | SEK 22,100.00 |
| 23.02.22 | Erik Manting | Other | Buy | SEK 211,680.00 |
SE0005003654
LEI529900AFBGFR7ZB50J95
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.